(Q36157329)

12 August 2017

1 reference

title

Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model (English)

1 reference

gastrointestinal stromal tumor

12 August 2017

1 reference

1 reference

Haesun Choi

1

1 reference

12 August 2017

publication date

1 July 2005

1 reference

12 August 2017

published in

Current Oncology Reports

1 reference

12 August 2017

volume

7

1 reference

12 August 2017

issue

4

1 reference

12 August 2017

page(s)

307-311

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-005-0055-4

12 August 2017

exact match

0 references

cites work

CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-005-0055-4

Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis

21 January 2018

1 reference

12 December 2020

Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation

1 reference

12 December 2020

Oncological applications of FDG PET imaging

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

1 reference

12 December 2020

Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIb: Therapy response monitoring in colorectal and lung tumours, head and neck cancer, hepatocellular carcinoma and sarcoma

1 reference

12 December 2020

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

12 December 2020

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

1 reference

12 December 2020

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors

1 reference

12 December 2020

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

12 December 2020

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

12 December 2020

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

12 December 2020

Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).

1 reference

12 December 2020

ARG tyrosine kinase activity is inhibited by STI571.

1 reference

12 December 2020

Principles and technology of PET scanning

1 reference

12 December 2020

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

12 December 2020

NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines

1 reference

12 December 2020

Management of malignant gastrointestinal stromal tumours

1 reference

12 December 2020

Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors

1 reference

12 December 2020

Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec

1 reference

12 December 2020

18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

1 reference

12 December 2020

Reporting results of cancer treatment

1 reference

12 December 2020

The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate

1 reference

12 December 2020

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

12 December 2020

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

1 reference

12 December 2020

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors

1 reference

12 December 2020

The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists

1 reference

12 December 2020

A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient

1 reference

12 December 2020

F-18 FDG PET imaging in gastrointestinal stromal tumor

1 reference

12 December 2020

Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

12 December 2020

10.1007/S11912-005-0055-4

Identifiers

DOI

1 reference

12 August 2017

1 reference